Home > News > Clinical Data Presented at ESMO
November 8th, 2004
Clinical Data Presented at ESMO
Abstract:
ACLARA BioSciences today announced that Sharat Singh, Ph.D., ACLARA's Chief Technical Officer, presented data from a pilot clinical trial demonstrating the ability of ACLARA's eTag(TM) assays to correctly differentiate responders from non-responders to Herceptin(R) treatment in patients with breast cancer. These data, subject to confirmation in larger, trials, suggest that the eTag System may be more accurate than the current standard at differentiating responders from non-responders to this widely used targeted therapy.
Source:
ACLARA BioSciences
Bookmark:
Possible Futures
Space Solar Power: Key to a Livable Planet Earth June 10th, 2013
Global Nanotechnology Drug Delivery Market 2012-2016 June 10th, 2013
Nanorobot tetanus treatment animation June 9th, 2013
New horizons to drive the future of Medicine: European Technology Platform on Nanomedicine intends to lead the domain June 8th, 2013
Nanomedicine
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013
Monell-led research identifies scent of melanoma: New research may lead to early non-invasive detection and diagnosis June 14th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
Announcements
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013
Polymer-coated catalyst protects "artificial leaf" June 17th, 2013
Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013
AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013